Cullinan Oncology(US:CGEM)2025-11-06 12:03Clinical Development - CLN-049 demonstrated a ~30% complete response rate in heavily pretreated patients with relapsed/refractory AML, with updated results to be presented at the 2025 ASH Annual Meeting[1] - The company plans to share initial clinical data for CLN-978 in autoimmune diseases in the first half of 2026[2] - The Phase 1 OUTRACE Program for CLN-978 is currently enrolling patients across multiple studies[6] - Taiho plans to initiate a rolling submission of an NDA for zipalertinib by year-end 2025, following a positive pre-NDA meeting with the FDA[3] - The core pipeline is now focused on T cell engagers, with discontinued programs CLN-619 and CLN-617[3] Financial Performance - Cash and investments totaled $475.5 million as of September 30, 2025, providing a runway into 2029[1] - Research and development expenses increased to $42.0 million for Q3 2025, compared to $35.5 million in Q3 2024[7] - General and administrative expenses were $13.6 million for Q3 2025, slightly up from $13.3 million in Q3 2024[7] - Net loss attributable to Cullinan was $50.6 million for Q3 2025, compared to $40.6 million for the same period in 2024[7] - Total stockholders' equity decreased to $451.4 million as of September 30, 2025, down from $590.3 million at the end of 2024[14]